


JC17 Rec'd PCT/PTO 20 SEP 2005

b.) Amendment to the Claims:

1. (Original) An antitussive which comprises, as an active ingredient, a tricyclic compound represented by Formula (I)



{wherein R<sup>1</sup> represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkoxy or halogen,


X<sup>1</sup>-X<sup>2</sup>-X<sup>3</sup> represents CR<sup>5</sup>=CR<sup>6</sup>-CR<sup>7</sup>=CR<sup>8</sup> [wherein R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup> and R<sup>8</sup> may be the same or different and each represents a hydrogen atom, substituted or unsubstituted lower alkyl, hydroxy, substituted or unsubstituted lower alkoxy, nitro, amino, mono(lower alkyl)-substituted amino, di(lower alkyl)-substituted amino, substituted or unsubstituted lower alkanoylamino or halogen], N(O)<sub>m</sub>=CR<sup>6</sup>-CR<sup>7</sup>=CR<sup>8</sup> (wherein R<sup>6</sup>, R<sup>7</sup> and R<sup>8</sup> have the same meanings as defined above, respectively and m represents 0 or 1), CR<sup>5</sup>=CR<sup>6</sup>-N(O)<sub>m</sub>=CR<sup>8</sup> (wherein R<sup>5</sup>, R<sup>6</sup>, R<sup>8</sup> and m have the same meanings as defined above, respectively), CR<sup>5</sup>=CR<sup>6</sup>-CR<sup>7</sup>=N(O)<sub>m</sub> (wherein R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup> and m have the same meanings as defined above, respectively), CR<sup>5</sup>=CR<sup>6</sup>-O (wherein R<sup>5</sup> and R<sup>6</sup> have the same meanings as defined above, respectively), CR<sup>5</sup>=CR<sup>6</sup>-S (wherein R<sup>5</sup> and R<sup>6</sup> have the same meanings as defined above, respectively), O-CR<sup>7</sup>=CR<sup>8</sup> (wherein R<sup>7</sup> and R<sup>8</sup> have the same meanings

as defined above, respectively),  $S-CR^7=CR^8$  (wherein  $R^7$  and  $R^8$  have the same meanings as defined above, respectively) or  $O-CR^7=N$  (wherein  $R^7$  has the same meaning as defined above),

Y represents  $-CH_2S-$ ,  $-CH_2SO-$ ,  $-CH_2SO_2-$ ,  $-CH_2O-$ ,  $-CH=CH-$ ,  $-(CH_2)_p-$  (wherein p represents an integer of 0 to 2),  $-SCH_2-$ ,  $-SOCH_2-$ ,  $-SO_2CH_2-$  or  $-OCH_2-$ , and

$R^2$  represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkoxy, amino, mono(substituted or unsubstituted lower alkyl)-substituted amino, di(substituted or unsubstituted lower alkyl)-substituted amino, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted aralkylamino, substituted or unsubstituted arylamino, or a substituted or unsubstituted heterocyclic group} or a pharmaceutically acceptable salt thereof.

2. (Original) An antitussive which comprises, as an active ingredient, a tricyclic compound represented by Formula (Ia)



[wherein R<sup>1</sup> and X<sup>1</sup>-X<sup>2</sup>-X<sup>3</sup> have the same meanings as defined above,  
respectively,


Y<sup>a</sup> represents -CH<sub>2</sub>SO<sub>2</sub>-, -SCH<sub>2</sub>-, -SOCH<sub>2</sub>-, -SO<sub>2</sub>CH<sub>2</sub>- or -OCH<sub>2</sub>- and

when Y<sup>a</sup> is -CH<sub>2</sub>SO<sub>2</sub>-, -SCH<sub>2</sub>-, -SOCH<sub>2</sub>- or -SO<sub>2</sub>CH<sub>2</sub>-,

R<sup>2a</sup> represents a hydrogen atom, substituted or unsubstituted lower alkyl,  
substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkoxy,  
amino, mono(substituted or unsubstituted lower alkyl)-substituted amino, di(substituted or  
unsubstituted lower alkyl)-substituted amino, substituted or unsubstituted aryl, substituted  
or unsubstituted heteroaryl, substituted or unsubstituted aralkylamino, substituted or  
unsubstituted arylamino, a substituted or unsubstituted heteroalicyclic group, or a  
substituted or unsubstituted nitrogen-containing heterocyclic group and

when Y<sup>a</sup> is -OCH<sub>2</sub>-,

R<sup>2a</sup> represents a hydrogen atom, trifluoromethyl, substituted or  
unsubstituted lower alkenyl, substituted or unsubstituted lower alkoxy, amino,  
mono(substituted or unsubstituted lower alkyl)-substituted amino, di(substituted or  
unsubstituted lower alkyl)-substituted amino, substituted or unsubstituted aryl, substituted  
or unsubstituted heteroaryl, substituted or unsubstituted aralkylamino, substituted or  
unsubstituted arylamino, a substituted or unsubstituted heteroalicyclic group, a substituted  
or unsubstituted nitrogen-containing heterocyclic group, or Formula (II)



(II)

(wherein n is 0 or 1; R<sup>3</sup> and R<sup>4</sup> may be the same or different and represents a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted aralkyl, or R<sup>3</sup> and R<sup>4</sup> may be combined together with the adjacent carbon atom thereto to form cycloalkyl; and Q represents hydroxy, substituted or unsubstituted lower alkoxy, amino or halogen)] or a pharmaceutically acceptable salt thereof.

3. (Original) The antitussive according to Claim 2, wherein Y<sup>a</sup> is -CH<sub>2</sub>SO<sub>2</sub>-, -SCH<sub>2</sub>-, -SOCH<sub>2</sub>- or -SO<sub>2</sub>CH<sub>2</sub>-.

4. (Original) The antitussive according to Claim 2, wherein Y<sup>a</sup> is -OCH<sub>2</sub>-.

5. (Original) The antitussive according to any of Claims 2 to 4, wherein R<sup>1</sup> is a hydrogen atom, substituted or unsubstituted lower alkoxy or halogen.

6. (Original) The antitussive according to any of Claims 2 to 4, wherein R<sup>1</sup> is a hydrogen atom.

7. (Currently Amended) The antitussive according to ~~any of Claims 2, 5 and 6~~ claim 2, wherein Y<sup>a</sup> is -CH<sub>2</sub>SO<sub>2</sub>-, -SO<sub>2</sub>CH<sub>2</sub>- or -OCH<sub>2</sub>- and R<sup>1</sup> is a hydrogen atom, substituted or unsubstituted lower alkoxy or halogen.


8. (Currently Amended) The antitussive according to ~~any of Claims 2, 5 and 6~~ claim 2, wherein Y<sup>a</sup> is -CH<sub>2</sub>SO<sub>2</sub>- or -SO<sub>2</sub>CH<sub>2</sub>- and R<sup>1</sup> is a hydrogen atom, substituted or unsubstituted lower alkoxy or halogen.

9. (Currently Amended) The antitussive according to ~~any of Claims 2, 5 and 6~~ claim 2, wherein Y<sup>a</sup> is -CH<sub>2</sub>SO<sub>2</sub>- and R<sup>1</sup> is a hydrogen atom, substituted or unsubstituted lower alkoxy or halogen.

10. (Currently Amended) The antitussive according to any of ~~Claims 2 to 9~~ claims 2 to 4, wherein X<sup>1</sup>-X<sup>2</sup>-X<sup>3</sup> is S-CR<sup>7</sup>=CR<sup>8</sup> (wherein R<sup>7</sup> and R<sup>8</sup> have the same meanings as defined above, respectively).

11. (Currently Amended) The antitussive according to any of ~~Claims 2 to 9~~  
claims 2 to 4, wherein  $X^1-X^2-X^3$  is  $CR^5=CR^6-CR^7=CR^8$  (wherein  $R^5$ ,  $R^6$ ,  $R^7$  and  $R^8$  have  
the same meanings as defined above, respectively).

12. (Currently Amended) The antitussive according to any of ~~Claims 2 to~~  
claims 2 to 4, wherein  $R^{2a}$  is Formula (II)




(wherein  $n$ ,  $R^3$ ,  $R^4$  and  $Q$  have the same meanings as defined above,  
respectively).

13. (Original) The antitussive according to Claim 12, wherein  $n$  is 0.


14. (Original) The antitussive according to Claim 13, wherein  $R^3$  is  
methyl,  $R^4$  is trifluoromethyl, and  $Q$  is hydroxy.

15. (Original) The antitussive according to Claim 2, wherein R<sup>1</sup> is a hydrogen atom, Y<sup>a</sup> is -CH<sub>2</sub>SO<sub>2</sub>-, X<sup>1</sup>-X<sup>2</sup>-X<sup>3</sup> is S-CR<sup>7</sup>=CR<sup>8</sup> (wherein R<sup>7</sup> and R<sup>8</sup> have the same meanings as defined above, respectively), and R<sup>2</sup> is Formula (III)



(III)

16. (Original) An antitussive which comprises, as an active ingredient, a tricyclic compound represented by Formula (Ib)




(Ib)

[wherein R<sup>1</sup> and X<sup>1</sup>-X<sup>2</sup>-X<sup>3</sup> have the same meanings as defined above, respectively,

Y<sup>b</sup> represents -CH<sub>2</sub>O-, -CH<sub>2</sub>S-, -CH<sub>2</sub>SO-, -CH=CH- or -(CH<sub>2</sub>)<sub>p</sub>- (wherein p has the same meaning as defined above) and

R<sup>2b</sup> represents Formula (III)



or a pharmaceutically acceptable salt thereof.

17. (Original) The antitussive according to Claim 16, wherein  $X^1-X^2-X^3$  is  $CR^5=CR^6-CR^7=CR^8$  (wherein  $R^5$ ,  $R^6$ ,  $R^7$  and  $R^8$  have the same meanings as defined above, respectively) or  $CR^5=CR^6-CR^7=N$  (wherein  $R^5$ ,  $R^6$  and  $R^7$  have the same meanings as defined above, respectively).

18. (Original) The antitussive according to Claim 16, wherein  $X^1-X^2-X^3$  is  $CR^5=CR^6-O$  (wherein  $R^5$  and  $R^6$  have the same meanings as defined above, respectively) or  $CR^5=CR^6-S$  (wherein  $R^5$  and  $R^6$  have the same meanings as defined above, respectively).

19. (Original) The antitussive according to Claim 16, wherein  $X^1-X^2-X^3$  is  $O-CR^7=CR^8$  (wherein  $R^7$  and  $R^8$  have the same meanings as defined above, respectively) or  $S-CR^7=CR^8$  (wherein  $R^7$  and  $R^8$  have the same meanings as defined above, respectively).



20. (Original) The antitussive according to any of Claims 16 to 19,  
wherein  $Y^b$  is  $-\text{CH}_2\text{O}-$ .

21. (Original) The antitussive according to any of Claims 16 to 19,  
wherein  $Y^b$  is  $-(\text{CH}_2)_p-$  (wherein  $p$  has the same meaning as defined above).

22. (Original) The antitussive according to Claim 21, wherein  $p$  is 0.

23. (Original) The antitussive according to Claim 21, wherein  $p$  is 2.

24. (Original) The antitussive according to any of Claims 16 to 19,  
wherein  $Y^b$  is  $-\text{CH}=\text{CH}-$ .

25. (Original) The antitussive according to any of Claims 16 to 19,  
wherein  $Y^b$  is  $-\text{CH}_2\text{S}-$  or  $-\text{CH}_2\text{SO}-$ .

26. (Original) A method for alleviation of a cough, which comprises a step of administering an effective amount of the tricyclic compound or the pharmaceutically acceptable salt thereof described in any of ~~Claims 1 to 25~~ claims 1 to 4 or 16-19.

Claims 27 (Cancelled).